415 related articles for article (PubMed ID: 18653247)
1. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting treatment effect of rituximab in MuSK myasthenia.
Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the management of refractory myasthenia gravis.
Zebardast N; Patwa HS; Novella SP; Goldstein JM
Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
[TBL] [Abstract][Full Text] [Related]
4. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
Stein B; Bird SJ
J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
[No Abstract] [Full Text] [Related]
6. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
7. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
8. Response to therapy in myasthenia gravis with anti-MuSK antibodies.
Evoli A; Bianchi MR; Riso R; Minicuci GM; Batocchi AP; Servidei S; Scuderi F; Bartoccioni E
Ann N Y Acad Sci; 2008; 1132():76-83. PubMed ID: 18567856
[TBL] [Abstract][Full Text] [Related]
9. Myasthenia gravis patients with anti-MuSK antibodies.
Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
[TBL] [Abstract][Full Text] [Related]
10. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
11. Frequency of seronegativity in adult-acquired generalized myasthenia gravis.
Chan KH; Lachance DH; Harper CM; Lennon VA
Muscle Nerve; 2007 Nov; 36(5):651-8. PubMed ID: 17654558
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
14. MuSK antibody-positive, seronegative myasthenia gravis in Korea.
Lee JY; Sung JJ; Cho JY; Oh DH; Kim HJ; Park JH; Lee KW; Choi YC; Vincent A
J Clin Neurosci; 2006 Apr; 13(3):353-5. PubMed ID: 16546389
[TBL] [Abstract][Full Text] [Related]
15. Anti-MuSK-positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles.
Kuwabara S; Nemoto Y; Misawa S; Takahashi H; Kawaguchi N; Hattori T
Acta Neurol Scand; 2007 Feb; 115(2):126-8. PubMed ID: 17212617
[TBL] [Abstract][Full Text] [Related]
16. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
Niks EH; van Leeuwen Y; Leite MI; Dekker FW; Wintzen AR; Wirtz PW; Vincent A; van Tol MJ; Jol-van der Zijde CM; Verschuuren JJ
J Neuroimmunol; 2008 Mar; 195(1-2):151-6. PubMed ID: 18384886
[TBL] [Abstract][Full Text] [Related]
17. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
[No Abstract] [Full Text] [Related]
18. [Seronegative myasthenia and myasthenia gravis with anti-MuSK antibody: a retrospective study of 20 cases].
Aubert S; Salort-Campana E; Franques J; Uzenot D; Pouget J
Rev Neurol (Paris); 2009 Nov; 165(11):901-10. PubMed ID: 19327804
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis.
Pompeo E; Tacconi F; Massa R; Mineo D; Nahmias S; Mineo TC
Eur J Cardiothorac Surg; 2009 Jul; 36(1):164-9. PubMed ID: 19339195
[TBL] [Abstract][Full Text] [Related]
20. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
